TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient-Reported Outcomes Measurement Information System - 29 Version
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in alcohol and other drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal absorption of iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anorectal fistula closing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of catheter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Speed of performing the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PERG examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and toleration of PF-04878691
Endpoint domain: Adverse events/effects
Primary endpoint: Perfusion of the index leg assessed by BOLD MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Perfusion of the index leg assessed by PBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Bone defect fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change in SIGH-ADS29
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive yield of malignancy on biliary brush cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Any Sex no Condom, Past 3 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Sex With Multiple Partners, Ever
Endpoint domain: Adverse events/effects
Primary endpoint: Drugs/Alcohol Use During Sex, Past 3 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adult subjects with treatment resistant hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of ER admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of admission to LTC facilities
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EDS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with a new PsA diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Measurement of periodontal inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in self monitoring of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 7-day abstinence point prevalence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of Clinical Attachment Level (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone quality and strength at the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehensive Geriatric Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Healthy Relationship Skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Daily OFF Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 Meter Walk Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falls Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DOLOPLUS pain score variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU outcome
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of People With Severe Scores on the Migraine Disability Assessment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of patients with adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: value of wavelength of DSPP in GCF from non-orthodontic patient with no root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: value of wavelength of DSPP in GCF from orthodontic patient with mild to moderate root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: value of wavelength of DSPP in GCF from child patient severe root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scoliotic curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response rate differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillary recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Change From Saline in Minimum FEV1 (Smokers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Change From Saline in Minimum FEV1 (Non-smokers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Change From Saline in Weighted Mean FEV1 (Smokers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Change From Saline in Weighted Mean FEV1 (Non-smokers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients who die during the index hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients who die during the follow-up period post-discharge
Endpoint domain: Mortality/survival
Primary endpoint: Time taken for burst suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Time taken for termination of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: total DVT + non-fatal PE + all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in average pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in average fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Dose-relative intensity (RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Extremity Mobility- 6-Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Extremity Strength- Chair Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lower Extremity Mobility and Endurance- Step Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of ESR1 LBD mutation variant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Degree of Olfactory Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants who Experienced an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Grade II-IV acute graft versus host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Survived Up To Hospital Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects at Least Moderately Improved
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of thrombotic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in SGRQ total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Responder Rate of Low Back Pain With No Increase in Pain Medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Low Back Pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Device and/or Procedure Related Adverse Event Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of children prescribed an antibiotic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Longitudinal depressive symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in time to all-cause treatment discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in perceived stress scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain measurement by the numerical rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measurement by the verbal rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with molecular alterations (FLT3 and NPM1 mutations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Beta 2 Microglobulin elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in perimeter measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictability of graft take
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Pain with movement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: work performances
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of thrombo-embolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absorption of metoprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of E.Faecalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Weekly General Hot Flash Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: TOF ratio of Recovery Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive change in baseline eating behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive change in baseline physical activity behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive change in baseline smoking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hemoglobin (Hgb) Level from Pre-dose to Mid-study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Hemoglobin (Hgb) Level from Pre-dose to End-of-study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Hemoglobin (Hgb) Level from Mid-study to End-of-study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Creatine Phosphokinase-MB Isoenzyme (CK-MB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Left Ventricular (LV) Ejection Fraction (EF) by Transthoracic Echocardiogram (TTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measure of Active Engagement and Transactional Supports (MAETS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Communication and Symbolic Behavior Scales (CSBS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vineland-3 Adaptive Behavior Scales Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Identify circulating tumor cells (CTC) for molecular characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Differentiated gene expression in CTCs before and after treatment start
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Phenotypical changes of immune cells due to anti-androgen treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in cardio metabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Growth inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intraoperative Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of local response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Existence of a suicide
Endpoint domain: Mortality/survival
Primary endpoint: Gene function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of neutral oral contrast agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent agreement between maximum P-wave assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline of Fibromyalgia Impact Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Box and Blocks Test (BBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in the Surface Area Measurement of the Target Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3 and Grade 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline to Day 28 on The Essential Tremor Rating Assessment Scale Performance Subscale (TETRAS-PS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to positivity (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Area Under the Curve (AUC) of Hydrogen (H2) production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants that completed calls
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of phone call
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients using Intervention materials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days until discharge from university hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time in glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of neuromuscular weakness syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MarzAA Activity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MarzAA Activity (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MarzAA Activity (AUCT1-T2 Normalized by Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inpatient Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Medication Adherence
Endpoint domain: Adverse events/effects
Primary endpoint: All cause mortality during zinc supplementation
Endpoint domain: Mortality/survival
Primary endpoint: Rate of severe illness requiring hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: number of questions during the consultation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rythmic capacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RLS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-hospital death after acute myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Global Assessment of Improvement (GAI) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality Rates
Endpoint domain: Mortality/survival
Primary endpoint: Difference between baseline and peak serum LPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically measured abnormality of laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High on-treatment platelet reactivity (HPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive Load
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Localization Ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Perceived Listening Effort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global Response at End of Intravenous Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of infectious endocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Clinical Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Youth Tested for HIV
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in recurrent priapism frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diary hours of Sitting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly caloric spend
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative frequency of patients in treatment groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Radiologic Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity of conditioning regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Number of MII Oocytes Retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Circulating levels of pro and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: amount of bone gained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in performance on cognitive measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Treatment Emergent Anti-hGH Binding Antibody Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants Initiating Treatment Within 90 Days of Diagnosis (Breast Cancer)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Participants Initiating Treatment Within 90 Days of Diagnosis (Lung Cancer)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Health-related Quality of Life Using the Visual Analogue Scale for Back Pain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health-related Quality of Life Using the Visual Analogue Scale for Leg Pain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical Functioning Using the Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety by Evaluating the Number of Serious Adverse Device Effects (SADEs), Adverse Device Effects (ADEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative positional injury (PPI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of HIV and other STIs
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic performance of Skeletal 99mTc-MDP SPECT/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rates (partial and complete responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Penetration of Raltegravir into Cerebrospinal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Hospital Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of DILI in antituberculosis therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of Cediranib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of gliclazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of gliclazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes